These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

513 related articles for article (PubMed ID: 29041905)

  • 1. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis.
    Kim HM; Lee J; Koo JS
    BMC Cancer; 2017 Oct; 17(1):690. PubMed ID: 29041905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of PD-L1 and prognosis in breast cancer: a meta-analysis.
    Zhang M; Sun H; Zhao S; Wang Y; Pu H; Wang Y; Zhang Q
    Oncotarget; 2017 May; 8(19):31347-31354. PubMed ID: 28430626
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of programmed cell death ligand-1 expression in breast cancer: A meta-analysis.
    Zhang Y; Tian J; Qu C; Tang Z; Wang Y; Li K; Yang Y; Liu S
    Medicine (Baltimore); 2020 Dec; 99(49):e23359. PubMed ID: 33285715
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Heterogeneity of PD-L1 expression in primary tumors and paired lymph node metastases of triple negative breast cancer.
    Li M; Li A; Zhou S; Xu Y; Xiao Y; Bi R; Yang W
    BMC Cancer; 2018 Jan; 18(1):4. PubMed ID: 29291717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-L1 expression and tumor infiltrating PD-1+ lymphocytes associated with outcome in HER2+ breast cancer patients.
    Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
    Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of PD-L1 in Breast Cancer: A Meta-Analysis.
    Wang C; Zhu H; Zhou Y; Mao F; Lin Y; Pan B; Zhang X; Xu Q; Huang X; Sun Q
    Breast J; 2017 Jul; 23(4):436-443. PubMed ID: 28079291
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoints in aggressive breast cancer subtypes.
    Zawlik I; Gablo N; Szymanska B; Pawlowska Z; Chudobinski C; Chalubinska-Fendler J; Morawiec Z; Zielinska-Blizniewska H; Morawiec-Sztandera A; Kolacinska A
    Neoplasma; 2016; 63(5):768-73. PubMed ID: 27468881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic and Clinicopathological Value of Programmed Death Ligand-1 in Breast Cancer: A Meta-Analysis.
    Guo Y; Yu P; Liu Z; Maimaiti Y; Wang S; Yin X; Liu C; Huang T
    PLoS One; 2016; 11(5):e0156323. PubMed ID: 27227453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of PD-1/PD-L1 in primary breast tumours and metastatic axillary lymph nodes and its correlation with clinicopathological parameters.
    Yuan C; Liu Z; Yu Q; Wang X; Bian M; Yu Z; Yu J
    Sci Rep; 2019 Oct; 9(1):14356. PubMed ID: 31591439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinicopathological and prognostic significance of PD-L1 expression in pancreatic cancer: A meta-analysis.
    Gao HL; Liu L; Qi ZH; Xu HX; Wang WQ; Wu CT; Zhang SR; Xu JZ; Ni QX; Yu XJ
    Hepatobiliary Pancreat Dis Int; 2018 Apr; 17(2):95-100. PubMed ID: 29576277
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinicopathological values of PD-L1 expression in HER2-positive breast cancer.
    Kurozumi S; Inoue K; Matsumoto H; Fujii T; Horiguchi J; Oyama T; Kurosumi M; Shirabe K
    Sci Rep; 2019 Nov; 9(1):16662. PubMed ID: 31723167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of PD-1/PD-L1 in triple-negative breast carcinoma and its significance].
    Zhang W; Xu GX; Li JJ; Liu X; Chen YJ; Zhang F
    Zhonghua Bing Li Xue Za Zhi; 2017 Jan; 46(1):20-24. PubMed ID: 28072971
    [No Abstract]   [Full Text] [Related]  

  • 13. Programmed death 1 Ligand 1 expression in breast cancer and its association with patients' clinical parameters.
    Li F; Ren Y; Wang Z
    J Cancer Res Ther; 2018 Jan; 14(1):150-154. PubMed ID: 29516978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PD-L1 expression of the residual tumor serves as a prognostic marker in local advanced breast cancer after neoadjuvant chemotherapy.
    Chen S; Wang RX; Liu Y; Yang WT; Shao ZM
    Int J Cancer; 2017 Mar; 140(6):1384-1395. PubMed ID: 27925176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Syntenin1/MDA-9 (SDCBP) induces immune evasion in triple-negative breast cancer by upregulating PD-L1.
    Liu J; Yang Y; Wang H; Wang B; Zhao K; Jiang W; Bai W; Liu J; Yin J
    Breast Cancer Res Treat; 2018 Sep; 171(2):345-357. PubMed ID: 29845474
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of programmed death ligand-1 and programmed death-1 in samples of invasive ductal carcinoma of the breast and its correlation with prognosis.
    Zhou T; Xu D; Tang B; Ren Y; Han Y; Liang G; Wang J; Wang L
    Anticancer Drugs; 2018 Oct; 29(9):904-910. PubMed ID: 30085937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of the predictive effect of PD-L1 expression on survival in early triple-negative breast cancer].
    Yue J; Wang X; Zhu AJ; Wang DY; Gao SL; Hu NL; Si YR; Zheng FC; Ju J; Wang Z; Yuan P
    Zhonghua Zhong Liu Za Zhi; 2023 Nov; 45(11):948-954. PubMed ID: 37968080
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic and clinicopathological value of PD-L1 expression in primary breast cancer: a meta-analysis.
    Huang W; Ran R; Shao B; Li H
    Breast Cancer Res Treat; 2019 Nov; 178(1):17-33. PubMed ID: 31359214
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The prevalence and clinicopathological features of programmed death-ligand 1 (PD-L1) expression: a pooled analysis of literatures.
    Lin Z; Xu Y; Zhang Y; He Q; Zhang J; He J; Liang W
    Oncotarget; 2016 Mar; 7(12):15033-46. PubMed ID: 26930715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.